Wedbush raised the firm’s price target on Pharvaris (PHVS) to $42 from $41 and keeps an Outperform rating on the shares. Most important in the Q4 update, Pharvaris reiterated all development timelines, the firm notes. The on-demand deucrictibant HAE submission remains on track for the first half of 2026, while management expects CHAPTER-3 results in the prophy setting by Q3 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
- Pharvaris price target lowered to $51 from $52 at RBC Capital
- Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
- Pharvaris reports Q4 EPS (EUR 0.72) vs. (EUR 0.64) last year
- Pharvaris announces publications of efficacy, safety evidence on deucrictibant